科济生物医药（上海）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CARsgen® Announces 2024 Interim Results 2024-08-29 20:50
CARsgen Announced 2023 Annual Results 2024-03-27 20:50
CARsgen Announces Formation of its Clinical Advisory Board 2023-11-20 21:50
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival 2023-10-12 20:50
CARsgen Announced 2023 Interim Results 2023-08-22 19:30
CARsgen Announced 2022 Annual Results and Business Updates 2023-03-22 20:50
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs 2022-10-31 21:30
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline 2022-08-24 20:50
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology 2022-08-18 20:50
CARsgen Appoints Dr. Hua Jiang as Executive Director 2022-08-02 20:50
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer 2022-04-07 23:42
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China 2022-03-23 20:50
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies 2022-03-23 20:50
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation 2022-01-17 21:50
1